← Browse by Condition
Medical Condition

sjogrens disease

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2
NCT06991114 Phase 2
Recruiting

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Enrollment
90 pts
Location
United States, Bulga...
Sponsor
Artiva Biotherapeutics, Inc.
View Trial →